Invention Grant
- Patent Title: Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof
-
Application No.: US17543033Application Date: 2021-12-06
-
Publication No.: US11891449B2Publication Date: 2024-02-06
- Inventor: Wenzhi Tian , Song Li , Dianze Chen
- Applicant: Immuneonco Biopharmaceuticals (Shanghai) Inc.
- Applicant Address: CN Shanghai
- Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
- Current Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
- Current Assignee Address: CN Shanghai
- Agency: Duane Morris LLP
- Agent Thomas J. Kowalski; Deborah L. Lu
- Priority: CN 2111195248.4 2021.10.13
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/02

Abstract:
The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
Public/Granted literature
- US20230114491A1 RECOMBINANT FUSION PROTEINS TARGETING CD47 AND CD24, PREPARATION AND USE THEREOF Public/Granted day:2023-04-13
Information query